Androgen excretion in women with a family history of breast cancer or with epithelial hyperplasia or cancer of the breast

Secreto, Giorgio; Fariselli, G; Bandieramonte, Gaetano; Recchione, C; Dati, Veronica; Pietro, S. Di

doi:10.1016/0277-5379(83)90389-9

Cited by 36 publications

(10 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The lack of significant differences for T and DHEA-S levels confirms previous findings [13]. Differences between serum levels and urinary excretion might be the reason for contrasting results [22,24]. Subnormal production of A had been observed previously [26].…”

Section: Discussionsupporting

confidence: 90%

“…A subnormal production of androgens was assumed to be a genetic marker of a disposition to breast cancer [26]. Elevated testosterone levels have been observed in premenopausal breast cancer patients [15], elevated testosterone and androstenedione levels in women with breast cancer or ductal hyperplasia as compared to controls [24]. This result has not been confirmed by others [13].…”

Section: Introductionmentioning

confidence: 65%

See 1 more Smart Citation

Androgen receptors, serum androgen levels and survival of breast cancer patients

Langer¹,

Kubista²,

Schemper³

et al. 1990

Arch Gynecol Obstet

View full text Add to dashboard Cite

Summary. Steroid receptor levels and serum androgen levels were determined in 61 breast cancer patients and 34 patients with non-malignant breast lesions. Testosterone and dehydroepiandrosterone-sulfate did not and androstenedione did show a difference between the two groups. Androgen levels had no influence on survival rates. Androgen receptor (AR) levels correlated with progesterone receptor levels, but not with estrogen receptor levels or with tumor stage. Patients with positive AR findings had a better survival rate; this was independent of tumor stage. AR findings may therefore be a prognostic index in breast cancer patients.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Introductionmentioning

confidence: 65%

Androgen receptors, serum androgen levels and survival of breast cancer patients

Langer¹,

Kubista²,

Schemper³

et al. 1990

Arch Gynecol Obstet

View full text Add to dashboard Cite

show abstract

“…This association has been consistently demonstrated in case-control and prospective studies in postmenopausal subjects (2)(3)(4)(5)(6)(7)(8), whereas the results in premenopausal women have been inconsistent (5). These studies of serum and plasma extended evidence of increases in urinary levels of testosterone in women with breast cancer (9)(10)(11). Testosterone is also found in nipple aspirate fluid (NAF) (12) and may be a valuable marker of risk.…”

mentioning

confidence: 88%

Circulating testosterone and prostate-specific antigen in nipple aspirate fluid and tissue are associated with breast cancer.

Sauter

Tichansky

Chervoneva

et al. 2002

Environ Health Perspect

View full text Add to dashboard Cite

Preliminary evidence has associated testosterone and prostate-specific antigen (PSA) with breast cancer. Our objective was to determine whether a) testosterone levels in nipple aspirate fluid (NAF), serum, or breast tissue are associated with breast cancer; b) testosterone levels in serum are associated with levels in NAF; c) PSA in NAF, serum, or breast tissue is associated with breast cancer; and d) serum PSA is associated with NAF PSA levels. We obtained 342 NAF specimens from 171 women by means of a modified breast pump. Additionally, we collected 201 blood samples from 99 women and 51 tissue samples from 41 subjects who underwent surgical resection for suspected disease. Women currently using birth control pills or hormone replacement therapy were excluded from the study. Controlling for age and menopausal status, serum testosterone was significantly increased in women with breast cancer (p = 0.002). NAF and serum testosterone levels were not associated. Neither NAF nor tissue testosterone was associated with breast cancer. Controlling for menopausal status and age, NAF PSA was significantly decreased in women with breast cancer (p < 0.001). We did not find serum PSA to be associated with breast cancer, although we found an indication that, in postmenopausal women, its levels were lower in women with cancer. Serum PSA was associated with NAF PSA in postmenopausal women (p < 0.001). PSA levels in cancerous tissue were significantly lower than in benign breast specimens from subjects without cancer (p = 0.011), whereas levels of PSA in histologically benign specimens from subjects with cancer were intermediate. Our results suggest that serum testosterone is increased and NAF PSA is decreased in women with breast cancer, with PSA expression being higher in normal than in cancerous breast tissues. NAF and serum PSA levels in postmenopausal women are correlated, suggesting that as laboratory assessment of PSA becomes more sensitive, serum PSA may become useful in identifying women with breast cancer.

show abstract

“…There was also a gradation in the incidence of anovulation as judged by endometrial histology, the highest being in women with the most marked hyperplasia. Recently Secreto et al [172] reported a higher excretion of urinary androstanediol in women with mammary dysplasia. They also found testosterone excretion was normal, as did Jones et al [89].…”

Section: (C) Androgensmentioning

confidence: 98%

Epidemiology and endocrinology of benign breast disease

Wang

Fentiman

1985

Breast Cancer Res Tr

View full text Add to dashboard Cite

Androgen excretion in women with a family history of breast cancer or with epithelial hyperplasia or cancer of the breast

Cited by 36 publications

References 20 publications

Androgen receptors, serum androgen levels and survival of breast cancer patients

Androgen receptors, serum androgen levels and survival of breast cancer patients

Circulating testosterone and prostate-specific antigen in nipple aspirate fluid and tissue are associated with breast cancer.

Epidemiology and endocrinology of benign breast disease

Contact Info

Product

Resources

About